Ads
related to: pfizer analgesic treatment
Search results
Results From The WOW.Com Content Network
PF-05089771 is a selective, small-molecule Na v 1.7 and Na v 1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic. [1] [2] [3] As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia. [4]
Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor as a treatment for pain via a novel mechanisms different from conventional pain-killer drugs. [1] Tanezumab was discovered and developed by Rinat Neuroscience [2] and was acquired by Pfizer in 2006.
The basic research leading to the discovery of COX-2 inhibitors has been the subject of at least two lawsuits. Brigham Young University has sued Pfizer, alleging breach of contract from relations BYU had with the company at the time of Simmons's work. [32] [33] A settlement was reached in April 2012 in which Pfizer agreed to pay $450 million.
Pfizer's main patent for Lyrica, for seizure disorders, in the UK expired in 2013. In November 2018, the Supreme Court of the United Kingdom ruled that Pfizer's second patent on the drug, for the treatment of pain, was invalid because there was a lack of evidence for the conditions it covered – central and peripheral neuropathic pain. From ...
The U.S. Food and Drug Administration has approved Pfizer's newest drug on the migraine market, Zavzpret (zavegepant) -- the first and only migraine treatment of its kind to be offered in nasal spray.
Former Pfizer sales representative John Kopchinski acted as a qui tam relator and filed a complaint in 2004 outlining the illegal conduct in the marketing of Bextra. [16] Kopchinski was awarded $51.5 million for his role in the case because the improper marketing of Bextra was the largest piece of the settlement at $1.8 billion.
Ad
related to: pfizer analgesic treatment